Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 11/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL462675 | 1.00 | KIF11 (0.62) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL28076975 | 0.85 | KIF11 (0.54) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL15212173 | 0.85 | KIF11 (0.68) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL28076974 | 0.85 | KIF11 (0.54) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL8212109 | 0.83 | MAPT (0.47) | KIF11KCNH2LTA4HLMNAHTT | |
| SCHEMBL1971090 | 0.82 | KCNN4 (0.48) | KIF11SMN1; SMN2 | |
| SCHEMBL8592606 | 0.82 | KIF11 (0.60) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL9694723 | 0.82 | KIF11 (0.60) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL4288651 | 0.82 | KIF11 (0.60) | KIF11KCNH2CA4LTA4HLMNA | |
| SCHEMBL17964412 | 0.82 | KIF11 (0.70) | KIF11KCNH2CA4LTA4HLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230235115-A1 | ESTER COMPOUND AND RESIN COMPOSITION | AJINOMOTO CO., INC. (JP) | 2023-07-27 | — | — | US | disclosed |
| US-20230235115-A1 | ESTER COMPOUND AND RESIN COMPOSITION | AJINOMOTO CO., INC. (JP) | 2023-07-27 | — | — | US | disclosed |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-11492620-B2 | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-11-08 | — | — | US | disclosed |
| US-20220049249-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2022-02-17 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-20210275564-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2021-09-09 | — | — | US | disclosed |
| US-20200360522-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-11-19 | — | — | US | disclosed |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | BONAC CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-2749565-B1 | NUCLEOSIDE PHOSPHORAMIDATES FOR PRODUCING NUCLEIC ACIDS | BONAC CORP (JP) | 2017-05-31 | — | — | EP | disclosed |
| EP-3098230-A1 | THIOETHER COMPOUND FOR THE PROTECTION OF THE 2'-HYDROXY GROUP IN NUCLEOSIDES TO BE USED IN OLIGONUCLEOTIDE SYNTHESIS. | Bonac Corporation (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2749565-A1 | GLYCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLYCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | Bonac Corporation (JP) | 2014-07-02 | — | — | EP | disclosed |
| US-20130177566-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING DISEASES | Celera Corporation (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130064843-A1 | Identification of conserved peptide blocks in homologous polypeptides | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| WO-2013027843-A1 | GLUCOSIDE COMPOUND, METHOD FOR PRODUCING THIOETHER, ETHER, METHOD FOR PRODUCING ETHER, METHOD FOR PRODUCING GLUCOSIDE COMPOUND, METHOD FOR PRODUCING NUCLEIC ACID | 株式会社ボナック (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-7850949-B2 | Purification of synthetic oligomers | MICHIGAN TECHNOLOGICAL UNIVERSITY (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080081902-A1 | PURIFICATION OF SYNTHETIC OLIGOMERS | MICHIGAN TECHNOLOGICAL UNIVERSITY | 2008-04-03 | — | — | US | disclosed |
| US-20070015927-A1 | New phosphoramidite compounds | POSTECH FOUNDATION (KR) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | KIF11 2519/4885KCNH2 3514/4885CA4 2075/4885 |
| US-20220049249-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF | POLN, POLM, DUT | KIF11 764/4885KCNH2 4793/4885CA4 1750/4885 |
| US-20070015927-A1 | New phosphoramidite compounds | TYMP, POLRMT, POLI | KIF11 2402/4885KCNH2 4643/4885CA4 1083/4885 |
| US-11492620-B2 | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof | POLN, POLM, DUT | KIF11 764/4885KCNH2 4793/4885CA4 1750/4885 |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | APOB, C1QBP, APOL1 | KIF11 1953/4885KCNH2 4474/4885CA4 4152/4885 |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | APOB, C1QBP, APOL1 | KIF11 1953/4885KCNH2 4474/4885CA4 4152/4885 |
| US-20080081902-A1 | PURIFICATION OF SYNTHETIC OLIGOMERS | RNGTT, NOP2, CAPZA2 | KIF11 2491/4885KCNH2 2927/4885CA4 2479/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | KIF11 2519/4885KCNH2 3514/4885CA4 2075/4885 |
| US-20200360522-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | APOB, C1QBP, APOL1 | KIF11 1953/4885KCNH2 4474/4885CA4 4152/4885 |
| US-20180079768-A1 | METHOD FOR PRODUCING GLYCOSIDE COMPOUNDS | TST, DIMT1, DERA | KIF11 2730/4885KCNH2 3866/4885CA4 87/4885 |
| US-20210275564-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | NSUN2, SLC10A1, BCDIN3D | KIF11 1172/4885KCNH2 4794/4885CA4 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.